NCT03411798View on ClinicalTrials.gov

Sequential Application of Yisaipu® and DMARDs in Treating Mild-to-Moderate AS

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

July 1, 2019

Study Completion Date

July 1, 2019

Conditions

Ankylosing Spondylitis

Interventions

DRUG

Yisaipu®

Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR \& CRP reduce to normal and BASDAI\<4) maintenance.

Trial Locations (1)

510515

Nanfang Hospital, Guangzhou

All Listed Sponsors

lead

Nanfang Hospital, Southern Medical University

OTHER

NCT03411798 - Sequential Application of Yisaipu® and DMARDs in Treating Mild-to-Moderate AS | Biotech Hunter | Biotech Hunter